February 2018

Feb 12, 2018, 07:30 ET CRANBURY, N.J., Feb. 12, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2017.  Recent Highlights Bremelanotide – Under development …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018 Read More »

Feb 07, 2018, 04:00 ET CRANBURY, N.J., Feb. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its …

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018 Read More »

CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the first healthy subjects have been dosed in a Phase 1 clinical study of PL-8177. The Phase 1 …

Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist Read More »